Print pageEmail pageRSS Feeds

We are building a strong, well-run business, structured to deliver sustainable results over the long term.

Along with biotechnology leadership, the ARIAD team is focused on its commitment to deliver long-term value to investors through solid business execution. That means maintaining disciplined cost control, thoughtful capital deployment and the highest standards of corporate governance.

Recent Press Releases
More >>
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency
Investor Downloads

Download Documentation AP26113 Phase 1/2 Update – ESMO 2014
Download Documentation Ponatinib Phase 2 GIST Trial – ESMO 2014
Download Documentation Corporate Presentation
More >>

ARIAD Stock Price: $5.71

Stock Symbol: ARIA

Stock Exchange: NASDAQ

Stock Quote at: 10/23/14

4:00 p.m. ET
(US Dollar)
CHANGE (%) Stock is Up 0.12 (2.15%)
DAY LOW$5.55
52 WK. HIGH$9.83
Minimum 20 minute delay
Refresh quote
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

You are now leaving this website. If you would like to continue, click Continue.